Xin Yu Koh
Overview
Explore the profile of Xin Yu Koh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
102
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spiegelberg D, Hwang L, Pua K, Kumar S, Koh X, Koh X, et al.
Sci Rep
. 2025 Jan;
15(1):1000.
PMID: 39762369
About 50% of all cancers carry a mutation in p53 that impairs its tumor suppressor function. The p53 missense mutation p53 (p53 in mice) is a hotspot mutation in various...
2.
Rosario B, Yi-En C, Barrera V, Diraviyam B, Low S, Lien C, et al.
Ann Acad Med Singap
. 2024 Jun;
52(6):327-330.
PMID: 38904515
No abstract available.
3.
Yeo S, Kua L, Tan J, Lim J, Wong F, Delos Santos M, et al.
Cancer Res Commun
. 2024 May;
4(6):1410-1429.
PMID: 38717140
Significance: Clinical application of EBVSTs armored with B7-H3-targeting CARs offer an attractive solution to translate off-the-shelf CAR T cells as therapy for solid tumors.
4.
Koh X, Koh X, Spiegelberg D, Jha P, Nestor M, Hwang L, et al.
Sci Rep
. 2022 Dec;
12(1):22564.
PMID: 36581692
The RON receptor tyrosine kinase is an exceptionally interesting target in oncology and immunology. It is not only overexpressed in a wide variety of tumors but also has been shown...
5.
Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine
Hwang L, Phang B, Liew O, Iqbal J, Koh X, Koh X, et al.
Cell Rep
. 2021 Aug;
36(6):109498.
PMID: 34380044
No abstract available.
6.
Ang S, Rosario B, Ngeow K, Koh X, Abdul Hamid S, Loi F, et al.
J Am Med Dir Assoc
. 2020 Jul;
21(9):1346-1348.
PMID: 32723534
In recent years, subacute care units (SCUs) have emerged as alternatives to acute hospitalization for selected emergency department (ED) patients who might benefit from a short period of inpatient stay...
7.
Koh X, Koh X, Hwang L, Ferrer F, Rahmat S, Lama D, et al.
Oncogene
. 2019 Aug;
38(48):7342-7356.
PMID: 31417186
Recepteur d'origine nantais (RON) receptor tyrosine kinase (RTK) and its ligand, serum macrophage-stimulating protein (MSP), are well-established oncogenic drivers for tumorigenesis and metastasis. RON is often found to be alternatively...
8.
Bradbury A, Trinklein N, Thie H, Wilkinson I, Tandon A, Anderson S, et al.
MAbs
. 2018 Feb;
10(4):539-546.
PMID: 29485921
Monoclonal antibodies are commonly assumed to be monospecific, but anecdotal studies have reported genetic diversity in antibody heavy chain and light chain genes found within individual hybridomas. As the prevalence...
9.
Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine
Hwang L, Phang B, Liew O, Iqbal J, Koh X, Koh X, et al.
Cell Rep
. 2018 Jan;
22(1):299-312.
PMID: 29298430
The large number of mutations identified across all cancers represents an untapped reservoir of targets that can be useful for therapeutic targeting if highly selective, mutation-specific reagents are available. We...
10.
Zheng S, Koh X, Goh H, Rahmat S, Hwang L, Lane D
Cancer Res
. 2017 Jun;
77(16):4342-4354.
PMID: 28655792
Chemotoxicity due to unwanted p53 activation in the bone marrow remains an unmet clinical challenge. Doxorubicin, a first-line chemotherapy drug, often causes myelosuppression in patients, thus limiting its effectiveness. In...